Tumor targeted combination therapeutic system for the effective treatment of drug resistant triple negative breast cancer

Int J Pharm. 2023 Apr 5:636:122821. doi: 10.1016/j.ijpharm.2023.122821. Epub 2023 Mar 11.

Abstract

Breast cancer has become the malignant tumor with the largest incidence, especially the drug resistant triple negative breast cancer (TNBC). The combination therapeutic system can play a better role in resisting drug resistant TNBC. In this study, dopamine and tumor targeted folic acid modified dopamine were synthesized as carrier materials to construct melanin-like tumor targeted combination therapeutic system. The optimized nanoparticles of CPT/Fe@PDA-FA10 with efficient loading of camptothecin and iron was achieved, which showed tumor targeted delivery ability, pH sensitive controlled release, effective photothermal conversion performance and excellent anti-tumor efficacy in vitro and in vivo. CPT/Fe@PDA-FA10 plus laser could significantly kill the drug resistant tumor cells, inhibit the growth of the orthotopic drug resistant triple negative breast cancer through apoptosis/ferroptosis/photothermal treatment, and had no significant side effects on the main tissues and organs. This strategy provided a new idea for the construction and clinical application of triple-combination therapeutic system as effective treatment for drug resistant triple negative breast cancer.

Keywords: Camptothecin; Drug resistance; Ferroptosis; Photothermal therapy; Triple negative breast cancer; Tumor targeted.

MeSH terms

  • Camptothecin
  • Cell Line, Tumor
  • Dopamine
  • Drug Carriers / therapeutic use
  • Humans
  • Nanoparticles*
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Dopamine
  • Camptothecin
  • Drug Carriers